Documentdetail
ID kaart

oai:arXiv.org:2411.02261

Onderwerp
Astrophysics - Cosmology and Nonga...
Auteur
Ballardini, Mario Barbieri, Nicola
Categorie

wetenschappen: astrofysica

Jaar

2024

vermelding datum

06-11-2024

Trefwoorden
results
Metriek

Beschrijving

Primordial oscillatory features in the power spectrum of curvature perturbations are sensitive probes of the dynamics of the early Universe and can provide insights beyond the standard inflationary scenario.

While these features have been the focus of extensive studies using cosmic microwave background anisotropy data, large-scale structure surveys now provide the opportunity to probe their effects at smaller scales with higher precision.

In this paper, we present a complete description of the nonlinear model for primordial oscillatory features in the context of time-sliced perturbation theory extending the results already presented in the literature.

We derive analytical expressions including novel contributions such as the mixed term between primordial oscillations and baryon acoustic oscillations, and we also calculate the corrections arising from the specific envelope of the oscillatory pattern, corresponding to a scale-dependent amplitude.

These results are compared with N-body simulations using the COLA method and show consistent behaviour across different scales.

Although the corrections are found to be small, they represent an important step towards fully characterising the nonlinear imprints of primordial features on the matter power spectrum.

Our results offer new predictions for future cosmological surveys that seek to detect these subtle signatures in the matter distribution.

;Comment: 45 pages, 5 figures

Ballardini, Mario,Barbieri, Nicola, 2024, Refining the nonlinear modelling of primordial oscillatory features

Document

Openen

Delen

Bron

Artikelen aanbevolen door ES/IODE AI

Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
gravis myasthenia study clinical phase baseline improvement mg-adl 340 week trial placebo period mg maintenance qw